TP53 and cancer: Although the vast majority of p53 mutants lose the wild-type function or exert a ‘dominant-negative’ effect on the remaining wild-type allele in cancer cells, many of them, particularly the missense and hotspot mutations, promote cancer development by acquiring the oncogenic GOF, and are therefore potential targets for anti-cancer therapy.